相似文献
1
Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients.
J Cereb Blood Flow Metab. 2010 Nov;30(11):1817-20. doi: 10.1038/jcbfm.2010.140. Epub 2010 Aug 18.
2
Blood platelet membrane fluidity and the exposition of membrane protein receptors in Alzheimer disease (AD) patients--preliminary Study.
Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):52-4. doi: 10.1097/00002093-200201000-00009.
3
Stem cell factor plasma levels are decreased in Alzheimer's disease patients with fast cognitive decline after one-year follow-up period: the Pythia-study.
J Alzheimers Dis. 2011;26(1):39-45. doi: 10.3233/JAD-2011-110008.
4
Increased platelet adhesion and thrombus formation in a mouse model of Alzheimer's disease.
Cell Signal. 2016 Dec;28(12):1863-1871. doi: 10.1016/j.cellsig.2016.08.017. Epub 2016 Sep 1.
5
Reduced P-selectin expression on circulating platelets after prolonged cold preservation in renal transplantation.
Clin Transplant. 2003 Oct;17(5):444-50. doi: 10.1034/j.1399-0012.2003.00073.x.
6
Activation and shedding of platelet glycoprotein IIb/IIIa under non-physiological shear stress.
Mol Cell Biochem. 2015 Nov;409(1-2):93-101. doi: 10.1007/s11010-015-2515-y. Epub 2015 Jul 10.
7
Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
Thromb Haemost. 2017 Jan 5;117(1):90-98. doi: 10.1160/TH16-02-0123. Epub 2016 Oct 20.
8
Influence of aflibercept on platelet activation profile.
Exp Eye Res. 2018 Oct;175:166-172. doi: 10.1016/j.exer.2018.06.009. Epub 2018 Jun 15.
9
Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients.
Mol Cell Biochem. 2017 Jun;430(1-2):69-80. doi: 10.1007/s11010-017-2955-7. Epub 2017 Feb 16.
10
Increased platelet activation in subjects chronically exposed to cadmium: A pilot study.
Platelets. 2016;27(2):136-42. doi: 10.3109/09537104.2015.1048215. Epub 2015 May 29.
引用本文的文献
1
Alzheimer's Disease-Thrombosis Comorbidity: A Growing Body of Evidence from Patients and Animal Models.
Cells. 2025 Jul 12;14(14):1069. doi: 10.3390/cells14141069.
2
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition.
Mol Neurobiol. 2025 Jul 10. doi: 10.1007/s12035-025-05192-x.
3
Associations between platelet indices and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study.
Alzheimers Res Ther. 2025 May 31;17(1):124. doi: 10.1186/s13195-025-01755-1.
4
Alterations in the Processing of Platelet APP (Amyloid Beta Precursor Protein) in Alzheimer Disease: The Possible Nexus.
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12525. doi: 10.1002/npr2.12525.
5
Association between platelet-to-high-density lipoprotein cholesterol ratio and cognitive function in older americans: insights from a cross-sectional study.
Sci Rep. 2024 Oct 28;14(1):25769. doi: 10.1038/s41598-024-77813-9.
6
One immune cell to bind them all: platelet contribution to neurodegenerative disease.
Mol Neurodegener. 2024 Sep 27;19(1):65. doi: 10.1186/s13024-024-00754-4.
7
Olive Oil Phenolics and Platelets-From Molecular Mechanisms to Human Studies.
Rev Cardiovasc Med. 2022 Jul 19;23(8):255. doi: 10.31083/j.rcm2308255. eCollection 2022 Aug.
8
Platelets and Neurodegenerative Diseases: Current Knowledge and Future Perspectives.
Int J Mol Sci. 2024 Jun 7;25(12):6292. doi: 10.3390/ijms25126292.
9
Communication Regarding the Myocardial Ischemia/Reperfusion and Cognitive Impairment: A Narrative Literature Review.
J Alzheimers Dis. 2024;97(4):1545-1570. doi: 10.3233/JAD-230886.
10
The Brain-Heart Axis: Neuroinflammatory Interactions in Cardiovascular Disease.
Curr Cardiol Rep. 2023 Dec;25(12):1745-1758. doi: 10.1007/s11886-023-01990-8. Epub 2023 Nov 23.
本文引用的文献
1
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
J Thromb Haemost. 2010 Jan;8(1):205-7. doi: 10.1111/j.1538-7836.2009.03659.x. Epub 2009 Oct 23.
2
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease.
Neurology. 2009 Sep 1;73(9):674-80. doi: 10.1212/WNL.0b013e3181b59bf3.
3
Cerebrovascular and cardiovascular pathology in Alzheimer's disease.
Int Rev Neurobiol. 2009;84:35-48. doi: 10.1016/S0074-7742(09)00403-6.
4
Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler.
J Alzheimers Dis. 2009;17(3):621-9. doi: 10.3233/JAD-2009-1079.
5
Contribution of vascular risk factors to the progression in Alzheimer disease.
Arch Neurol. 2009 Mar;66(3):343-8. doi: 10.1001/archneur.66.3.343.
6
Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors.
Clin Neurol Neurosurg. 2009 May;111(4):327-30. doi: 10.1016/j.clineuro.2008.10.006. Epub 2008 Nov 25.
7
Rate of progression in Alzheimer's disease correlates with coated-platelet levels--a longitudinal study.
Transl Res. 2008 Sep;152(3):99-102. doi: 10.1016/j.trsl.2008.07.001. Epub 2008 Aug 9.
8
Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned.
Dement Geriatr Cogn Disord. 2008;25(3):226-31. doi: 10.1159/000114450. Epub 2008 Jan 30.
9
Hyperresponsiveness of platelets in ischemic stroke.
Thromb Haemost. 2007 Jun;97(6):974-8.
10
Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.
Dement Geriatr Cogn Disord. 2007;23(6):439-45. doi: 10.1159/000102017. Epub 2007 Apr 26.
Zotero 插件